{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:10:37Z","timestamp":1768414237316,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00277-016-2668-0","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:45:03Z","timestamp":1461285903000},"page":"1107-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study"],"prefix":"10.1007","volume":"95","author":[{"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Wasle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Endri","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pitini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"2668_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1023\/A:1008375931236","volume":"10","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419\u20131432","journal-title":"Ann Oncol"},{"key":"2668_CR2","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2012.47.7315","volume":"31","author":"OW Press","year":"2013","unstructured":"Press OW (2013) Selection of first-line therapy for advanced follicular lymphoma. J Clin Oncol 31:1496\u20131498","journal-title":"J Clin Oncol"},{"key":"2668_CR3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA et al (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268\u2013276","journal-title":"J Clin Oncol"},{"key":"2668_CR4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423","journal-title":"Blood"},{"key":"2668_CR5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A et al (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506\u20131513","journal-title":"J Clin Oncol"},{"key":"2668_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","volume":"127","author":"R Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ et al (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48\u201354","journal-title":"J Cancer Res Clin Oncol"},{"key":"2668_CR7","first-page":"671","volume":"8","author":"K Ruffert","year":"1989","unstructured":"Ruffert K, Jahn H, Syrbe G et al (1989) Bendamustine as an alternative approach to treat malignant non-Hodgkin\u2019s lymphoma. Z Klin Med 8:671\u2013674","journal-title":"Z Klin Med"},{"key":"2668_CR8","first-page":"501","volume":"15","author":"M Herold","year":"1992","unstructured":"Herold M, Keinert K, Anger G (1992) Risk-adapted combined radiotherapy and chemotherapy for Hodgkin\u2019s disease. Onkologie 15:501\u2013505","journal-title":"Onkologie"},{"key":"2668_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309\u2013317","journal-title":"Clin Cancer Res"},{"key":"2668_CR10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"2668_CR11","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952","journal-title":"Blood"},{"key":"2668_CR12","doi-asserted-by":"crossref","unstructured":"Burke JM, Van der Jagt RH, Kahl BS, et al. (2012) Differences in quality of life between bendamustine plus rituximab compared with standard first- line treatments in patients with previously untreated advanced indolent non-Hodgkin\u2019s lymphoma or mantle cell lymphoma. Blood a155","DOI":"10.1182\/blood.V120.21.155.155"},{"issue":"suppl 4","key":"2668_CR13","first-page":"89","volume":"22","author":"F Morschhauser","year":"2011","unstructured":"Morschhauser F, Seymour JF, Feugier P et al (2011) Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 22(suppl 4):89","journal-title":"Ann Oncol"},{"key":"2668_CR14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361\u20131392","journal-title":"Blood"},{"key":"2668_CR15","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Swerdlow SH, Campo E, Harris NL (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon","edition":"4"},{"key":"2668_CR16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"2668_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid M et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"2668_CR18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular Lymphoma International Prognostic Index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"2668_CR19","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","volume":"5","author":"AG Singal","year":"2014","unstructured":"Singal AG, Higgins PD, Waljee AK (2014) A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 5:e45","journal-title":"Clin Transl Gastroenterol"},{"key":"2668_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D385N6C9JF","volume":"16","author":"HS Alamdari","year":"2010","unstructured":"Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW (2010) Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 16:1","journal-title":"Dermatol Online J"},{"key":"2668_CR21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1078155214533368","volume":"21","author":"MJ Fallon","year":"2015","unstructured":"Fallon MJ, Heck JN (2015) Fatal Stevens-Johnson syndrome\/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustinetherapy. J Oncol Pharm Pract 21:388\u2013392","journal-title":"J Oncol Pharm Pract"},{"key":"2668_CR22","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2668-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2668-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2668-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T18:50:47Z","timestamp":1692298247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2668-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2668-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]}}}